NEW YORK (GenomeWeb) – CombiMatrix said recently in its Form 10-Q that it executed a secured promissory note for $350,000 bearing a 10 percent annual interest rate.

In its document filed with the US Securities and Exchange Commission, the company said that it executed the promissory note on May 20 with ACC Investment. The note is secured by certain laboratory equipment used in its microarray services business and will be payable over a 36-month period. As of June 30 the fair value of the note was about $312,000.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.